| Bioactivity | LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma kallikrein inhibitor under the study for angioedema, with an EC50 less than 100 nM in cell[1]. | ||||||||||||
| Target | EC50：< 100 nM (kallikrein in cell). | ||||||||||||
| Name | LSP-249 | ||||||||||||
| CAS | 1801253-04-2 | ||||||||||||
| Formula | C24H22ClN5O | ||||||||||||
| Molar Mass | 431.92 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Andrew Mcdonald, et al. Therapeutic inhibitory compounds. Patent. WO2016011209A1. |
LSP-249
CAS: 1801253-04-2 F: C24H22ClN5O W: 431.92
LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma kallikrein inhibitor under the study for angioed
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.